...
首页> 外文期刊>African Journal of Pharmacy and Pharmacology >Synthesis, characterization, and anticancer activity against human breast cancer cell-line T47D studies of metal ion Cu(II) complex with 2,4,5-triphenylimidazole ligand
【24h】

Synthesis, characterization, and anticancer activity against human breast cancer cell-line T47D studies of metal ion Cu(II) complex with 2,4,5-triphenylimidazole ligand

机译:用2,4,5-三苯基咪唑配体对金属离子Cu(II)络合物进行人乳腺癌细胞系T47D研究的合成,表征和抗癌活性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The complex of metal ion Cu(II) with the ligand 2,4,5-trifenilimidazol has been successfully synthesized with mole ratio of metal and ligand 1:2 in N,N-dimethylformamide as a solvent. Complex synthesis results obtained green light crystalline solid. Complex absorbs UV-Vis light at 529 nm. Fourier transform infrared (FTIR) characterization results indicate occurrence of bonding of metals and ligand that is Cu-N in region 422.38 cm-1. Results of elemental analyzer and Atomic Absorption Spectroscopy (AAS) analysis show the complex formed has the formula [Cu(L)2(H2O)2].Cl2. The molecular formula is also supported by the Thermal Gravimetric Analyzer data. Thermal Gravimetric Analyzer (TGA) analysis results showed that there was no water in the crystalline complex compounds. The cytotoxicity test complex compounds made by the method of 3-(4,5-dimetiltiazol-2-yl)-2,5-difeniltetrazolium bromide (MTT) and the IC50 value of complex obtained 72.139 μg/ml.
机译:金属离子Cu(II)的复合物用配体2,4,5-三苯胺扎唑并以N,N-二甲基甲酰胺中的金属和配体1:2的摩尔比成功地合成,作为溶剂。复杂的合成结果获得了绿光结晶固体。复杂的吸收紫外线灯,529 nm。傅里叶变换红外(FTIR)表征结果表明金属和配体的键合的发生在422.38cm-1中的Cu-n。元素分析仪和原子吸收光谱(AAS)分析的结果表明,形成的复合物具有式[Cu(1)2(H2O)2] .Cl2。分子式也由热重分析仪数据支撑。热重分析仪(TGA)分析结果表明,晶体复合物化合物中没有水。通过3-(4,5-二维唑-2-基)-2,5-二烯烯烯醇辛溴化物(MTT)和络合物的IC50值获得的方法和络合物的方法进行细胞毒性测试复合化合物。获得72.139μg/ ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号